BAT1806 vs Sarilumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline
BAT1806 · Tofidence
Marketed by Organon and partners
NCT03830203 · Phase 3 · completed
The study was randomized, quadruple-blind, and actively controlled with EU-licensed Actemra, enrolling 621 participants; its primary endpoint was the clinical ACR20 response at 6 months. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response (6 months): ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins (met)
Result source: NCT03830203
Sarilumab
Marketed by Sanofi and partners
NCT01061736 · Phase 2/3 · completed
This was a large, randomized, triple-blind, placebo-controlled trial with adequate sample size and hard clinical/functional/radiographic primary endpoints (ACR20 response, HAQ-DI, and van der Heijde-modified Total Sharp Score). In the confirmatory Part B, both sarilumab 150 mg and 200 mg every 2 weeks met all three primary endpoints with highly significant differences from placebo (p<0.0001), and Part A also showed significant ACR20 responses for several sarilumab doses. The positive, well-designed confirmatory results support strong evidence for sarilumab.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Reported efficacy
DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106) (met)
Result source: NCT02332590
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BAT1806 | Sarilumab |
|---|---|---|
| ACR20 | 69.9% vs 67.9%avs reference tocilizumabNCT03830203 | 66.4% vs 33.4%+33 vs placeboNCT0106173611 other results
|
| ACR50 | —Not posted · NCT03830203 | 40.8% vs 18.2%+22.6 vs placeboNCT017095782 other results
|
| ACR70 | —Not posted · NCT03830203 | 16.3% vs 7.2%+9.1 vs placeboNCT017095782 other results
|
| DAS28-CRP remission | —Not posted · NCT03830203 | 28.8% vs 7.2%+21.6 vs placeboNCT017095784 other results
|
| HAQ-DI, change | —Not posted · NCT03830203 | -0.5 vs -0.3−0.2 vs placeboNCT017095784 other results
|
| Modified Sharp score, change | —Not posted · NCT03830203 | —Trial running · NCT03414502 |
ACR20
- BAT1806
- 69.9% vs 67.9%avs reference tocilizumabNCT03830203
- Sarilumab
- 66.4% vs 33.4%+33 vs placeboNCT01061736
11 other results
- 60.9% vs 33.7% NCT01709578
- 58% vs 33.4% NCT01061736
- 57.5% vs 14.8% NCT02293902
- 55.8% vs 33.7% NCT01709578
- 65.4% vs 46.2% NCT01061736
- 67.9% vs 14.8% NCT02293902
- 72% vs 46.2% NCT01061736
- 66.7% vs 46.2% NCT01061736
- 62% vs 46.2% NCT01061736
- 49% vs 46.2% NCT01061736
- 71.7% vs 58.4% NCT02332590
ACR50
- BAT1806
- —Not posted · NCT03830203
- Sarilumab
- 40.8% vs 18.2%+22.6 vs placeboNCT01709578
2 other results
- 37% vs 18.2% NCT01709578
- 45.7% vs 29.7% NCT02332590
ACR70
- BAT1806
- —Not posted · NCT03830203
- Sarilumab
- 16.3% vs 7.2%+9.1 vs placeboNCT01709578
2 other results
- 19.9% vs 7.2% NCT01709578
- 23.4% vs 11.9% NCT02332590
DAS28-CRP remission
- BAT1806
- —Not posted · NCT03830203
- Sarilumab
- 28.8% vs 7.2%+21.6 vs placeboNCT01709578
4 other results
- 17.9% vs 3.9% NCT01709578
- 24.9% vs 7.2% NCT01709578
- 17.1% vs 3.9% NCT01709578
- 34.2% vs 13.5% NCT02332590
HAQ-DI, change
- BAT1806
- —Not posted · NCT03830203
- Sarilumab
- -0.5 vs -0.3−0.2 vs placeboNCT01709578
4 other results
- -0.5 vs -0.3 NCT01709578
- -0.6 vs -0.3 NCT01709578
- -0.5 vs -0.3 NCT01709578
- -0.6 vs -0.4 NCT02332590
Modified Sharp score, change
- BAT1806
- —Not posted · NCT03830203
- Sarilumab
- —Trial running · NCT03414502
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BAT1806: 0 of 4 rows · Sarilumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | BAT1806 | Sarilumab |
|---|---|---|
| Dropout rate | — | 13.5%200 mg q2wa NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 show 35 more results—200 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 5.9%150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 8%150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 11.8%100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 26%100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 49.7%Sarilumab + Disease Modifying Anti NCT01146652 · Phase 3 · combination 40.5%Sarilumab Monotherapy NCT01146652 · Phase 3 · monotherapy —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 10.3%200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 27.7%200 mg q2w NCT01709578 · Phase 3 30.9%150 mg q2w NCT01709578 · Phase 3 22.6% NCT03449758 · Phase 4 · registry result, not featured evidence —200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy —150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 40%200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 13.3%150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 12.5%200 mg NCT02293902 · Phase 3 · registry result, not featured evidence 8.6%150 mg NCT02293902 · Phase 3 · registry result, not featured evidence —Sarilumab Rescue NCT02293902 · Phase 3 · registry result, not featured evidence 13.5%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 3.6%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 7.1%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 5.7%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence —150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 13.4%200 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —200mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 10.8%150 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —150mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 23.5%200 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence 18.4%150 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | — | 7.7%200 mg q2wa NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 show 35 more results—200 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 3.9%150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 2%150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 5.9%100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 26%100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 26.5%Sarilumab + Disease Modifying Anti NCT01146652 · Phase 3 · combination 13.5%Sarilumab Monotherapy NCT01146652 · Phase 3 · monotherapy —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 6%200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 9.2%200 mg q2w NCT01709578 · Phase 3 9.9%150 mg q2w NCT01709578 · Phase 3 10.7% NCT03449758 · Phase 4 · registry result, not featured evidence —200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy —150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 33.3%200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 13.3%150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 10%200 mg NCT02293902 · Phase 3 · registry result, not featured evidence 7.4%150 mg NCT02293902 · Phase 3 · registry result, not featured evidence —Sarilumab Rescue NCT02293902 · Phase 3 · registry result, not featured evidence 11.5%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 1.8%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 5.4%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 3.8%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence —150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 10.4%200 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —200mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 7.7%150 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —150mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 17.6%200 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence 16.3%150 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence |
| Serious AEs | — | 0%200 mg q2wa NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 show 35 more results12.5%200 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 0%150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 0%150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 9.5%150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 7.7%150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 5.9%100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 6%100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 0%100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 6.9%100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 32.3%Sarilumab + Disease Modifying Anti NCT01146652 · Phase 3 · combination 24.3%Sarilumab Monotherapy NCT01146652 · Phase 3 · monotherapy 4.9%200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 17.5%200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 5.4%200 mg q2w NCT01709578 · Phase 3 3.3%150 mg q2w NCT01709578 · Phase 3 11.9% NCT03449758 · Phase 4 · registry result, not featured evidence 6.5%200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 3.3%150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 20%200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 0%150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 6.3%200 mg NCT02293902 · Phase 3 · registry result, not featured evidence 9.9%150 mg NCT02293902 · Phase 3 · registry result, not featured evidence 6.9%Sarilumab Rescue NCT02293902 · Phase 3 · registry result, not featured evidence 5.8%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 7.1%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 1.8%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 0%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 10.1%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence —200 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 3%200mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —150 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 1.5%150mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 5.9%200 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence 2%150 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | — | 200 mg q2wa neutropenia 19.6% (placebo 0%) upper respiratory tract infection 5.9% (placebo 3.9%) accidental overdose 3.9% (placebo 9.8%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 show 32 more results200 mg q2w neutropenia 14.9% (placebo 0%) upper respiratory tract infection 9.5% (placebo 3.9%) alanine aminotransferase increased 8.1% (placebo 0%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 150 mg q2w accidental overdose 5.8% (placebo 9.8%) alanine aminotransferase increased 5.8% (placebo 0%) nasopharyngitis 3.8% (placebo 5.9%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 150 mg qw neutropenia 10% (placebo 0%) accidental overdose 6% (placebo 9.8%) rheumatoid arthritis 6% (placebo 2%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 150 mg q2w neutropenia 9.7% (placebo 0%) alanine aminotransferase increased 8.4% (placebo 0%) upper respiratory tract infection 8.4% (placebo 3.9%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 150 mg qw injection site erythema 11.5% (placebo 0%) hypertension 7.7% (placebo 2%) neutropenia 7.7% (placebo 0%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 100 mg q2w hypertension 3.9% (placebo 2%) nasopharyngitis 3.9% (placebo 5.9%) accidental overdose 2% (placebo 9.8%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 100 mg qw neutropenia 12% (placebo 0%) urinary tract infection 6% (placebo 2%) accidental overdose 4% (placebo 9.8%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 100 mg q2w accidental overdose 10.3% (placebo 9.8%) hypertension 6.9% (placebo 2%) neutropenia 3.4% (placebo 0%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 100 mg qw accidental overdose 6.9% (placebo 9.8%) rheumatoid arthritis 6.9% (placebo 2%) hypertension 3.4% (placebo 2%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 neutropenia 18.2% accidental overdose 17.3% upper respiratory tract infection 15.9% NCT01146652 · Phase 3 · combination accidental overdose 18% neutropenia 16.2% rheumatoid arthritis 14.4% NCT01146652 · Phase 3 · monotherapy 200 mg neutropenia 13.6% injection site erythema 7.6% bronchitis 6.5% NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 200 mg nasopharyngitis 18.8% neutropenia 18.4% bronchitis 12.8% NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 200 mg q2w neutropenia 12% (placebo 1.1%) urinary tract infection 7.1% (placebo 6.6%) alanine aminotransferase increased 5.4% (placebo 1.1%) NCT01709578 · Phase 3 150 mg q2w neutropenia 12.7% (placebo 1.1%) hypertriglyceridaemia 6.1% (placebo 1.7%) injection site erythema 6.1% (placebo 0%) NCT01709578 · Phase 3 neutropenia 19% bronchitis 11.9% nausea 11.9% NCT03449758 · Phase 4 · registry result, not featured evidence 200 mg q2w nasopharyngitis 45.2% injection site erythema 19.4% hepatic function abnormal 12.9% NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 150 mg q2w nasopharyngitis 43.3% rheumatoid arthritis 13.3% oropharyngeal pain 10% NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 200 mg q2w nasopharyngitis 33.3% stomatitis 26.7% neutropenia 20% NCT02373202 · Phase 3 · registry result, not featured evidence · combination 150 mg q2w neutropenia 33.3% nasopharyngitis 26.7% contusion 20% NCT02373202 · Phase 3 · registry result, not featured evidence · combination 200 mg nasopharyngitis 28.8% (placebo 14.8%) neutropenia 11.3% (placebo 0%) stomatitis 10% (placebo 3.7%) NCT02293902 · Phase 3 · registry result, not featured evidence 150 mg nasopharyngitis 33.3% (placebo 14.8%) neutropenia 12.3% (placebo 0%) hepatic function abnormal 9.9% (placebo 4.9%) NCT02293902 · Phase 3 · registry result, not featured evidence nasopharyngitis 32.8% (placebo 14.8%) stomatitis 12.1% (placebo 3.7%) neutropenia 10.3% (placebo 0%) NCT02293902 · Phase 3 · registry result, not featured evidence 200 mg neutropenia 11.5% alanine aminotransferase increased 9.6% injection site erythema 7.7% NCT02057250 · Phase 3 · registry result, not featured evidence 200 mg injection site erythema 7.1% injection site pruritus 7.1% neutropenia 7.1% NCT02057250 · Phase 3 · registry result, not featured evidence 150 mg neutropenia 17.9% pharyngitis 8.9% bronchitis 7.1% NCT02057250 · Phase 3 · registry result, not featured evidence 150 mg neutropenia 17% sinusitis 5.7% injection site erythema 3.8% NCT02057250 · Phase 3 · registry result, not featured evidence 150 mg upper respiratory tract infection 13.3% neutropenia 6.4% sinusitis 6.4% NCT02057250 · Phase 3 · registry result, not featured evidence 200mg q2w neutropenia 16.4% hypertension 6% upper respiratory tract infection 6% NCT02121210 · Phase 3 · registry result, not featured evidence 150mg q2w neutropenia 12.3% injection site erythema 7.7% upper respiratory tract infection 4.6% NCT02121210 · Phase 3 · registry result, not featured evidence 200 mg q2w neutropenia 15.7% injection site erythema 7.8% accidental overdose 5.9% NCT01768572 · Phase 3 · registry result, not featured evidence 150 mg q2w nasopharyngitis 12.2% neutropenia 12.2% injection site erythema 8.2% NCT01768572 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 23 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sarilumab
show 1 more result
show 35 more results
show 35 more results
show 35 more results
show 48 more results
show 50 more results
show 40 more results
show 6 more results
show 6 more results
show 48 more results
show 51 more results
show 35 more results
+ 46 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1806's landscape · Sarilumab's landscape